Company Overview
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Why Investors Should Care
Generates a return on equity of 65.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 16.2%.
Revenue has grown at a 191.3% CAGR over the past five years.
Trades at a P/E of 7.4, below the sector median of 25.4.
Maintains a net profit margin of 100.0%.
Carries low leverage with a debt-to-equity ratio of 0.12.
Recent Developments
- Dec 2025 Revenue of $283.06M (+20.4% YoY); net profit $287.20M.
- Trailing 12 Months Year-on-year growth — revenue +24.4%, earnings +56.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 191.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 191.33% |
| 1 Year: | 24.40% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 56.30% |
Stock Price Performance
| 1 Year: | +76.77% |
| 6 Months: | +5.48% |
| 3 Months: | -0.50% |
| 1 Month: | +0.82% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.37 · Neutral
P/E of 7.40 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 65.0%.
- Excellent profit margin of 100.0%.
- Compounding revenue at 191.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AUPH Aurinia Pharmaceuticals Inc. R2K | 15.98 | 7.40 | $2.06B | 0.00% | 16.20% | 64.98% | 191.33% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.00K | 29.00K | 230.00K | 29.00K | 30.00K | 29.00K | 29.00K | 50.03M | 914.00K | 6.62M | 14.67M | 23.40M | 21.62M | 28.19M | 55.78M | 28.43M | 34.41M | 41.49M | 54.52M | 45.09M | 50.30M | 57.19M | - | - | 62.47M | 70.01M | 73.47M | 77.11M | 77.70M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.57M | 7.12M | 8.18M | 8.80M | 6.50M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 53.89M | 62.89M | 65.29M | 68.31M | 71.20M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.51M | 42.70M | 35.55M | 35.08M | 29.78M |
| Operating Income | -14.89M | -17.14M | -24.07M | -34.84M | -27.06M | -26.86M | -42.31M | -8.05M | -50.54M | -47.13M | -50.35M | -32.70M | -37.88M | -35.99M | -9.50M | -28.10M | -29.58M | -16.17M | -16.26M | -29.67M | -13.25M | -1.51M | - | - | 23.38M | 20.20M | 29.75M | 33.24M | 41.42M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.27M | 28.14M | 37.93M | 41.60M | 49.75M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07M | 1.12M | 1.10M | 1.05M | 1.01M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.35M | 22.16M | 31.96M | 35.69M | 43.92M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00M | 643.00K | 411.00K | -175.10M | 9.57M |
| Net Income | -14.10M | -16.38M | -23.45M | -34.46M | -25.93M | -26.54M | -42.13M | -8.07M | -50.38M | -47.01M | -50.26M | -33.32M | -37.63M | -35.52M | -8.99M | -26.05M | -26.21M | -11.49M | -13.45M | -26.88M | -10.75M | 722.00K | - | - | 23.34M | 21.51M | 31.55M | 210.79M | 34.35M |
| Diluted EPS | - | - | - | - | -0.23 | -0.24 | -0.34 | -0.06 | -0.40 | -0.37 | -0.39 | -0.25 | -0.27 | -0.25 | -0.06 | -0.18 | -0.18 | -0.08 | -0.09 | -0.19 | -0.07 | 0.01 | - | - | 0.16 | 0.16 | 0.23 | 1.53 | 0.25 |
| R&D Expense | - | - | - | - | 13.84M | 11.08M | 12.24M | - | 9.83M | 10.09M | 20.07M | - | 12.62M | 11.53M | 10.97M | - | 13.16M | 12.65M | 13.61M | - | 5.55M | 4.08M | 3.05M | - | 5.74M | 7.43M | 8.44M | - | 7.47M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 463.00K | 318.00K | 50.12M | - | 134.03M | 175.51M | 235.13M | 283.06M |
| Cost of Revenue | - | - | - | - | 5.66M | 14.15M | 28.25M | 32.66M |
| Gross Profit | - | - | - | - | 128.37M | 161.37M | 206.88M | 250.39M |
| Operating Expenses | - | - | - | - | 239.84M | 253.06M | 188.47M | 143.83M |
| Operating Income | -55.24M | -90.94M | -104.29M | - | -111.47M | -91.69M | 18.42M | 106.56M |
| EBITDA | - | - | - | - | -103.65M | -63.05M | 31.73M | 137.94M |
| Interest Expense | - | - | - | - | 0 | 2.77M | 4.83M | 4.33M |
| Pretax Income | - | - | - | - | -106.35M | -77.47M | 7.45M | 114.16M |
| Tax Provision | - | - | - | - | 1.83M | 551.00K | 1.70M | -173.04M |
| Net Income | -53.08M | -88.39M | -102.68M | - | -108.18M | -78.02M | 5.75M | 287.20M |
| Diluted EPS | - | -0.95 | -0.87 | - | -0.76 | -0.54 | 0.04 | 2.07 |
| R&D Expense | 41.38M | 52.87M | 50.33M | 51.14M | 44.99M | 49.64M | 20.79M | 32.51M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 324.30M | 463.66M | - | 470.86M | 548.06M | 550.64M | 751.59M |
| Current Assets | - | - | - | - | - | 442.54M | 424.80M | 446.60M | 491.97M |
| Cash & Equivalents | - | - | 306.02M | 272.35M | - | 94.17M | 48.88M | 83.43M | 80.21M |
| Inventory | - | - | - | - | - | 24.75M | 39.70M | 39.23M | 45.69M |
| Receivables | - | - | - | - | - | 13.48M | 24.09M | 36.54M | 41.45M |
| Total Liabilities | - | - | 25.70M | 55.91M | - | 65.42M | 170.11M | 173.17M | 170.26M |
| Current Liabilities | - | - | 11.29M | 32.00M | - | 46.11M | 77.19M | 97.76M | 93.72M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 8.09M | 97.61M | 79.37M | 74.81M |
| Total Equity | 177.92M | 135.72M | 298.60M | 407.75M | - | 405.44M | 377.95M | 377.48M | 581.33M |
| Shares Outstanding | - | - | - | - | - | 142.27M | 143.83M | 140.88M | 132.32M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -51.61M | -63.59M | -69.86M | - | -79.53M | -33.46M | 44.39M | 135.66M |
| Investing Cash Flow | -65.00K | 7.78M | -158.19M | - | -60.63M | -6.71M | 39.26M | -32.77M |
| Financing Cash Flow | 4.01M | 243.85M | 194.38M | - | 2.43M | -5.13M | -49.09M | -106.11M |
| Capital Expenditure | - | - | - | - | -292.00K | -718.00K | -281.00K | -252.00K |
| Free Cash Flow | - | - | - | - | -79.82M | -34.18M | 44.11M | 135.41M |
| Net Change in Cash | - | - | - | - | -137.73M | -45.30M | 34.56M | -3.22M |
| Share Buybacks | - | - | - | - | 0 | 0 | 40.24M | 98.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 95.8% | 91.9% | 88.0% | 88.5% |
| Operating Margin % | -11,930.9% | -28,598.4% | -208.1% | - | -83.2% | -52.2% | 7.8% | 37.6% |
| Net Margin % | -11,464.1% | -27,794.0% | -204.9% | - | -80.7% | -44.5% | 2.4% | 101.5% |
| ROE % | -39.1% | -29.6% | -25.2% | - | -26.7% | -20.6% | 1.5% | 49.4% |
| ROCE % | - | -29.1% | -24.2% | - | -26.2% | -19.5% | 4.1% | 16.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Tang Capital Management, LLC | 9.51% | 12.23M | $193.96M |
| 2 | Blackrock Inc. | 6.10% | 7.85M | $124.43M |
| 3 | NEA Management Company, LLC | 3.09% | 3.97M | $62.96M |
| 4 | Two Sigma Investments, LP | 2.67% | 3.43M | $54.38M |
| 5 | Arrowstreet Capital, Limited Partnership | 2.55% | 3.28M | $52.09M |
| 6 | State Street Corporation | 1.97% | 2.53M | $40.08M |
| 7 | Morgan Stanley | 1.74% | 2.23M | $35.41M |
| 8 | Marshall Wace LLP | 1.46% | 1.87M | $29.73M |
| 9 | Renaissance Technologies, LLC | 1.29% | 1.66M | $26.39M |
| 10 | Shaw D.E. & Co., Inc. | 1.22% | 1.57M | $24.95M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AUPH
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta, July 06, 2026--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, obinutuzumab o…
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?
Is AUPH a good stock to buy? We came across a bullish thesis on Aurinia Pharmaceuticals Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AUPH. Aurinia Pharmaceuticals Inc.’s share was trading at $1…
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.…
AUPH — Frequently Asked Questions
What is the current share price of Aurinia Pharmaceuticals Inc. (AUPH)?
As of 2026-07-14 21:23 PDT, Aurinia Pharmaceuticals Inc. (AUPH) trades at $15.98 on NasdaqGM. Its 52-week range is $8.62 to $18.62.
What is the market capitalisation of AUPH?
Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalisation of $2.06B on NasdaqGM.
What is the P/E ratio of AUPH?
AUPH trades at a trailing price-to-earnings (P/E) ratio of 7.40. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.64.
What is the return on equity (ROE) of AUPH?
AUPH has a return on equity (ROE) of 64.98%. Its return on capital employed (ROCE) is 16.20%.
Is AUPH a good stock to buy?
This page provides a data-driven analysis of Aurinia Pharmaceuticals Inc. (AUPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.